Months af­ter Re­gen­eron se­cured FDA ap­proval for 12-week Eylea reg­i­men, No­var­tis buys speedy US re­view for its ri­val

No­var­tis’ brolu­cizum­ab could do to Re­gen­eron’s Eylea what the flag­ship eye treat­ment did to Roche’s Lu­cen­tis, some ex­perts have pre­dict­ed. Vas Narasimhan has shout­ed from the rooftops the promise of brolu­cizum­ab even be­fore his el­e­va­tion to No­var­tis chief. On Mon­day, No­var­tis came one step clos­er to launch­ing its chal­lenge to Re­gen­eron’s for­mi­da­ble block­buster, se­cur­ing a speedy re­view for brolu­cizum­ab for use in wet age-re­lat­ed mac­u­lar de­gen­er­a­tion (AMD), set­ting it up for ap­proval by the end of this year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.